Pyronaridine As a Bromodomain-Containing Protein 4--Terminal Bromodomain (BRD4-BD1) Inhibitor: Database Mining, Molecular Docking, and Molecular Dynamics Simulation
Authors
Affiliations
BRD4 (bromodomain-containing protein 4) is an epigenetic reader that realizes histone proteins and promotes the transcription of genes linked to cancer progression and non-cancer diseases such as acute heart failure and severe inflammation. The highly conserved -terminal bromodomain (BD1) recognizes acylated lysine residues to organize the expression of genes. As such, BD1 is essential for disrupting BRD4 interactions and is a promising target for cancer treatment. To identify new BD1 inhibitors, a SuperDRUG2 database that contains more than 4600 pharmaceutical compounds was screened using techniques. The efficiency of the AutoDock Vina1.1.2 software to anticipate inhibitor-BRD4-BD1 binding poses was first evaluated based on the co-crystallized R6S ligand in complex with BRD4-BD1. From database screening, the most promising BRD4-BD1 inhibitors were subsequently submitted to molecular dynamics (MD) simulations integrated with an MM-GBSA approach. MM-GBSA computations indicated promising BD1 binding with a benzonaphthyridine derivative, pyronaridine (SD003509), with an energy prediction (Δ) of -42.7 kcal/mol in comparison with -41.5 kcal/mol for a positive control inhibitor (R6S). Pharmacokinetic properties predicted oral bioavailability for both ligands, while post-dynamic analyses of the BRD4-BD1 binding pocket demonstrated greater stability for pyronaridine. These results confirm that studies can provide insight into novel protein-ligand regulators, specifically that pyronaridine is a potential cancer drug candidate.
Dong J, Hao X BMC Chem. 2024; 18(1):247.
PMID: 39696643 PMC: 11657568. DOI: 10.1186/s13065-024-01362-5.
Ibrahim M, Hassan A, Mohamed E, Mekhemer G, Sidhom P, El-Tayeb M PLoS One. 2024; 19(11):e0312100.
PMID: 39546470 PMC: 11567563. DOI: 10.1371/journal.pone.0312100.